SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Beeline Medicines Announces Presentation of Phase 2 Results of Afimetoran in Systemic Lupus Erythematosus at ACR Convergence 2026

All three afimetoran doses met the primary endpoint with a placebo-adjusted difference in SRI-4 re

Related stories